explore -WSS

explore

author：hotspot 2025-09-28 21:58:59 - browse：38

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： For BCIs, commercial hurdles may be bigger than scientific ones

WSS

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Timeline: Special counsel's probe into Trump's handling of classified documents

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Alexander Hamilton and the argument for universal insurance

As the dark side of IVF slowly comes into focus, even more transparency is needed

Will biotech layoffs continue through 2023?

hotspot

explore

leisure time

Activists slam private health insurers over coverage restrictions

Dramatically reducing cancer deaths requires the PASTEUR Act

Dobbs anniversary: the lost opportunity of abortion as health care

The mammogram wars are not over

Medical leaders decry Supreme Court decision on affirmative action

Gilgo Beach: Police identify another victim in serial killing investigation

BioMarin wins approval for gene therapy to treat hemophilia A

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

Novavax promises a turnaround & Lilly roils the obesity market

Interest rates are at a 22

knowledge

Biden announces an advanced cancer research initiative

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

Gilgo Beach: Police identify another victim in serial killing investigation

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Moscow blames Kyiv for missile attacks in southern Russia as Kremlin forces pound Ukrainian village

What Mike Pence has said that could be used in a Donald Trump trial

leisure time

hotspot

hotspot

Wikipedia